

BILLING CODE	Must use valid NDC
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
STATUS	Prior Authorization Required

Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older. It exhibits agonist activity at serotonin 5-HT2 receptors. Fintepla has a black box warning for valvular heart disease and pulmonary arterial hypertension.

Dravet syndrome is an epilepsy that usually presents in the first year of life with recurrent seizures which are often prolonged and triggered by fever. With time, other types of seizures may occur, as well as intellectual disability, neurological abnormalities, behavioral issues, and other comorbidities. Complete seizure control is rarely achievable. In 80-85% of cases, variants in the SCN1A gene are present.

Lennox

Fintepla (fenfluramine) will be considered for coverage when the following criteria are met:

Dravet Syndrome

For **initial** authorization:

1. Member is 2 years old or older; AND
2. Medication must be prescribed by or in consultation with a neurologist; AND
3. Member has a diagnosis of seizures associated with Dravet Syndrome; AND

reauthorization:

1. Chart notes must document a reduction in convulsive seizure frequency since starting Fintepla.

If all the above requirements are met, the medication will be approved for an additional 12 months.



8. Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial [published online ahead of print, 2019 Dec 2]. *JAMA Neurol.* 2019;77(3):300-308. doi:10.1001/jamaneurol.2019.4113
9. Devi N, Madaan P, Asrar MM, Sahu JK, Bansal D. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome. *Epilepsia.* 2019;60(13):2134-2140. doi:10.1177/0749074919861803